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oD. Raoult, Unité de Recherche sur les Maladies Infectieuses et Tro-
picales Emergentes, Faculté de Médecine, URMITE CNRS-IRD 198
UMR 6236, Université de la Méditerranée, Marseille, France
E-mail: didier.raoult@gmail.comPaper citation is currently the only way to evaluate what is ‘hot’
in international literature. To evaluate this using adapted key-
words, we retrieved all articles, in early May 2015, that were
cited more than 100 times according to ISI from Thomson
Reuters, in infectious disease. We selected articles from the
New England Journal of Medicine, the Lancet and the Journal of
the American Medical Association as the most cited medical
journals and from the Lancet Infectious Disease, Clinical In-
fectious Diseases and Clinical Microbiology and Infections from
the years 2012 and 2013, as the three, broad-spectrum, most
cited, infectious diseases journals. During these years, more
than 100 000 papers on infectious diseases were recorded in
ISI, of which 200 were cited more than 100 times (0.2%).
Among the three big medical journals, the citation rate (for all
articles and reviews) was higher in the New England Journal of
Medicine with average citation rate of 97, with 234 papers
above 100 citations of which 27 were from infectious diseasesBLE 1. Highly cited papers (>100 citations) from 2012 and 2013
012/2013 N Engl J Med Lancet JAMA
umber articles/reviews 709 1600 1230
factor 141 114 481
umber of citations in 2015 per papers
(Infect Dis/Med Microbiol)
97 30 25
rticles cited >100 times 234 (33%) 133 (8%) 51 (4%)
alaria 0 2 0
uberculosis 3 0 0
IV 5 4 1
epatitis 4 1 1
7 N9 3 3 0
ERS coronavirus 1 0 0
esistance to antibiotics + Neo antibiotics 0 1 0
accines 3 0 0
ycology 0 0 0
icrobiota 2 0 1
otal >100 Infect. Dis.; p < 0.001 27 (4%) 15 (1%) 4 (0.4%
7N9, avian inﬂuenza virus H7N9; HIV, human immunodeﬁciency virus; MERS, Middle East res
f the American Medical Association; JID, The Journal of Infectious Diseases; CID, Clinical I
Clinical Microbiology and Infection © 2015 European Society of C(4% of papers published in the journal). For the Lancet 133
papers were recorded, 15 of which were from our ﬁeld (1% of
published papers), compared with 51 with four from our ﬁeld in
the Journal of the American Medical Association. Indeed, the
New England Journal of Medicine for these 2 years published
signiﬁcantly more highly cited papers in our ﬁeld. As for the
infectious diseases journals, Lancet Infectious Disease did bet-
ter: 12 (7%) of its articles reached 100 citations, nearly as many
as the Lancet, its mother journal; Clinical Infectious Diseases
had six articles and Clinical Microbiology and Infection had four
and they were comparable within the infectious diseases ﬁeld
(see Table 1).
Three major points emerged. First, the microbiota in the
international literature reach 35% of most cited papers but its
appearance is negligible in infectious diseases journals and the
best medical journals. In Clinical Microbiology and Infection,
edited by F. Baquero, we published a supplementary issue [1]
and I edited a themed issue [2] to emphasize this ﬁeld. It is
rapidly growing with most highly cited papers being issued from
the Nature group (29) and Science (13), but this subject is sadly
escaping the infectious disease and general medical literature. In
contrast, attention paid to rare and regional diseases such as
avian inﬂuenza virus H7N9 or Middle East respiratory syn-
drome coronavirus was very low in infectious diseases journalsin infectious diseases
JID CID CMI Total ISI
164 955 556 5214 >100.00
44 48 31
40 17 11
12 (7%) 6 (0,6%) 4 (0,7%) 200 (0.2%)
0 0 0 2 (3%) 30% 5 (2.5%)
2 1 0 6 (9%) 13 (6.5%)
2 0 0 11 (17%) 35 (17.5%)
0 0 0 5 8% 26 (13%)
0 0 0 8 13% 9 (4.5%)
1 0 0
3 4 2 10 16% 26 (13%)
2 0 0 5 8% 14 (7%)
0 1 1 2 3% 11 (5.5%)
0 0 1 3 5% 70 (35%)
) 12 (7%) 6 (0.6%) 4(0.7%) 64 200 (1.2%)
piratory syndrome; N Engl J Med, The New England Journal of Medicine; JAMA, Journal
nfectious Disease; CMI, Clinical Microbiology and Infections.
Clin Microbiol Infect 2015; 21: 803–804
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
http://dx.doi.org/10.1016/j.cmi.2015.05.037
804 Clinical Microbiology and Infection, Volume 21 Number 9, September 2015 CMIbut high in the Lancet and the New England Journal of Medicine.
We recently reported on the disproportion of highly cited
papers on regional diseases in leading journals, not being
practical when considering their readership as doctors [3].
Finally, antibiotic resistance and evaluation of treatments and
new antibiotic compounds are comparable in the journal
literature (13%) and in infectious disease journals (16%) but are
neglected in leading medical journals (2%). The ‘big three’ dis-
eases (tuberculosis, human immunodeﬁciency virus infection
and malaria) are equally published (30% in all sources), although
malaria is neglected, considering the fatalities that it causes in
the world. Finally, pneumonia (besides rare emerging viruses)Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectand diarrhoeas are the more neglected ﬁeld in all journals when
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